A Phase 4 interventional study of Clopidogrel and Ticagrelor in Non-ST Segment Elevation Myocardial Infarction and ST Segment Elevation Myocardial Infarction, sponsored by Inha University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-10-01.
Sponsored by Inha University Hospital · Phase 4, Interventional, and Treatment
Ticagrelor is a non-thienophyridine, direct P2Y12 blocker that is more potent than clopidogrel and is associated with less interindividual variability. In the PLATO trial, it was found to be superior to clopidogrel with respect to cardiovascular outcomes and total mortality without increasing the risk of bleedings.
More potent and reversible receptor bindings are possible explanation for the superior outcomes. Beside the potent effect on inhibition of antiplatelet function, ticagrelor has previously been demonstrated to increase adenosine levels by inhibiting adenosine re-uptake in tissue level and can induce adenosine triphosphate (ATP) release from human red cells, which both stimulate vasodilation of in red blood cells.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 76 is below the median of 148 across 1,595 interventional studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →Inha University Hospital is the lead sponsor of 37 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Males and Females
History of stroke or transient ischemic attack
Clopidogrel 600mg loading
Drug: Clopidogrel
Ticagrelor 180mg loading
Drug: Ticagrelor
Clopidogrel 600mg loading
Ticagrelor 180mg loading
Index of microcirculatory resistance (IMR) measured after successful coronary intervention
Time frame: IMR will be immediately assessed after successful PCI patients within 48hr from admission
wall motion score index on three month later TTE from index PCI
Time frame: TTE will be assessed in all enrolled patients 3 month later from index PCI
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inha University Hospital